GLP1 Academy
Learn · Emerging science

What Is Retatrutide? The Science Behind the Next Generation of Weight-Loss Medication

By GLP-1 Academy · Brought to you by Longevity Academy · October 2026

The rapid development of medications that target metabolic hormones has transformed the treatment of obesity and type 2 diabetes. Semaglutide demonstrated the therapeutic potential of targeting the glucagon-like peptide-1 (GLP-1) receptor. Tirzepatide expanded that approach by simultaneously activating GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Now researchers are studying a third approach: retatrutide, an investigational medication developed by Eli Lilly and Company that activates three metabolic hormone receptors—GLP-1, GIP and glucagon.

Retatrutide has sometimes been described in popular media as a “GLP-3” drug. That terminology is scientifically inaccurate: there is no GLP-3 hormone receptor involved. Retatrutide is more accurately described as a triple hormone receptor agonist. Lilly itself specifically cautions against the “GLP-3” terminology.

The distinction matters because retatrutide represents more than simply a stronger GLP-1 medication. Its pharmacology is designed to influence several complementary systems involved in appetite, glucose regulation, energy balance and fat metabolism.

Early and Phase 3 clinical results suggest this strategy could produce substantial weight loss and metabolic improvements. However, an equally important fact needs to accompany any discussion of retatrutide:

Retatrutide is still investigational. It is not currently FDA-approved, and products being marketed to consumers as compounded or “research-grade” retatrutide should not be considered legitimate alternatives to an approved prescription medication.

What Exactly Is Retatrutide?

Retatrutide, previously identified as LY3437943, is a peptide-based medication developed by Eli Lilly and Company. It is designed as a single molecule capable of activating three receptors:

GLP-1 — glucagon-like peptide-1

GIP — glucose-dependent insulinotropic polypeptide

Glucagon

In clinical trials, retatrutide is administered by once-weekly subcutaneous injection.

This triple-receptor strategy distinguishes retatrutide from two major drugs already used for obesity treatment.

Semaglutide, the active ingredient in Wegovy and Ozempic, primarily activates the GLP-1 receptor.

Tirzepatide, the active ingredient in Zepbound and Mounjaro, activates both GIP and GLP-1 receptors.

Retatrutide adds glucagon-receptor agonism to the equation.

That additional pathway may prove important because glucagon signaling can affect energy expenditure and substrate metabolism in ways that differ from appetite suppression alone.

How Retatrutide Works

Body weight is regulated by a complex neuroendocrine system involving the brain, gastrointestinal tract, pancreas, liver, adipose tissue and other organs. Retatrutide attempts to influence several components of this system simultaneously.

1. GLP-1 receptor activation

GLP-1 is a naturally occurring incretin hormone released primarily after food consumption.

Activating GLP-1 receptors can enhance glucose-dependent insulin secretion, suppress inappropriate glucagon secretion, delay gastric emptying and influence appetite-regulating centers within the central nervous system.

For people taking GLP-1-based medications, one of the most noticeable effects is often reduced hunger and increased satiety.

People may feel satisfied after eating smaller portions and experience less persistent food-related thinking.

This reduction in caloric intake is one of the major mechanisms through which GLP-1 receptor agonists produce weight loss.

2. GIP receptor activation

GIP is another incretin hormone released following nutrient intake.

Its biology is complex, but pharmacologic GIP receptor activation in combination with GLP-1 signaling appears capable of improving glucose control and contributing to body-weight reduction.

GIP signaling influences insulin secretion and metabolic processes involving adipose tissue. The success of tirzepatide demonstrated that simultaneous GIP and GLP-1 receptor activation can produce substantial metabolic effects.

Retatrutide retains those two pathways while adding a third.

3. Glucagon receptor activation

The glucagon component is what makes retatrutide particularly interesting scientifically.

Glucagon is traditionally associated with increasing blood glucose through hepatic glucose production. At first glance, stimulating the glucagon receptor might therefore seem counterproductive in someone with diabetes or metabolic dysfunction.

The physiology is more nuanced.

Glucagon signaling also influences lipid metabolism, substrate utilization and energy expenditure. Researchers hypothesize that carefully balancing glucagon activation with GLP-1 and GIP activity could increase energy expenditure while the incretin components simultaneously control appetite and glucose metabolism.

In the Phase 2 obesity trial, investigators specifically proposed that adding glucagon-receptor activation could augment effects on energy intake, substrate utilization and energy expenditure.

This raises an intriguing possibility: retatrutide may potentially influence both sides of the energy-balance equation—reducing energy intake while also altering how energy is utilized.

That hypothesis remains an active area of research.

What Have the Weight-Loss Trials Found?

The initial results generated considerable scientific attention.

A randomized Phase 2 trial published in The New England Journal of Medicine included 338 adults with obesity or overweight plus at least one weight-related condition.

After 48 weeks, average weight reductions were:

  • 8.7% with 1 mg
  • 17.1% with 4 mg
  • 22.8% with 8 mg
  • 24.2% with 12 mg

The placebo group lost approximately 2.1%.

Importantly, participants receiving the higher doses were still losing weight at 48 weeks, suggesting that the full treatment effect had not necessarily been reached.

The Phase 3 program has subsequently produced even larger reductions in some populations.

In the TRIUMPH-4 trial involving adults with obesity or overweight and knee osteoarthritis, participants receiving the 12-mg dose lost an average of 28.7% of body weight at 68 weeks.

TRIUMPH-1 subsequently reported an average reduction of approximately 28.3% at 80 weeks with 12 mg, corresponding to about 70 pounds in that study population.

These percentages are averages—not guarantees of what any individual would experience.

Furthermore, some Phase 3 findings initially became available through company announcements before complete peer-reviewed publications were available. The scientific strength of evidence should therefore be judged trial by trial rather than treating every reported percentage as equivalent.

Retatrutide and Type 2 Diabetes

Retatrutide is also being extensively studied as a glucose-lowering therapy.

In the Phase 3 TRANSCEND-T2D-1 trial, adults with type 2 diabetes treated with retatrutide experienced average A1C reductions of approximately 1.7 to 2.0 percentage points at 40 weeks, depending on dose.

Participants receiving 12 mg lost approximately 16.8% of their body weight during the same period.

The lower weight-loss percentage compared with some obesity trials is not necessarily surprising. People with type 2 diabetes frequently experience less weight reduction with incretin-based therapies than people without diabetes.

Another Phase 3 study, TRIUMPH-2, subsequently reported average weight loss of up to 20.8% at 80 weeks among participants with type 2 diabetes and obesity or overweight.

Together, these findings suggest that retatrutide could potentially become both an obesity therapy and a powerful metabolic therapy if regulatory authorities ultimately determine that its benefit-risk profile supports approval.

Potential Effects Beyond Weight Loss

One of the most interesting aspects of retatrutide research is that investigators are studying outcomes extending beyond the number on the scale.

Lilly's development program includes research involving obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and kidney outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD).

Some early findings are notable.

Fatty liver disease

A Phase 2a analysis involving participants with MASLD demonstrated large reductions in liver fat.

At 24 weeks, mean relative liver-fat reductions were approximately 81% with 8 mg and 82% with 12 mg. Among participants receiving 12 mg, 86% reached liver-fat levels below 5% in this substudy.

These findings are scientifically interesting because MASLD is closely associated with obesity, insulin resistance and cardiometabolic disease.

However, reductions in liver fat should not automatically be interpreted as proof that retatrutide prevents advanced liver disease or improves long-term clinical outcomes. Those questions require appropriately designed outcome studies.

Osteoarthritis

Weight reduction can substantially reduce mechanical stress on weight-bearing joints.

In TRIUMPH-4, retatrutide produced both major weight loss and substantial improvements in knee osteoarthritis pain and physical function. At the highest studied dose, average WOMAC pain scores declined by approximately 75.8%.

This raises a broader issue in obesity medicine: successful obesity treatment can potentially improve diseases that are caused or aggravated by excess adiposity rather than simply lowering body weight.

Obstructive sleep apnea

Phase 3 findings have also demonstrated improvements in obstructive sleep apnea. In a TRIUMPH-1 substudy, Lilly reported reductions in apnea-hypopnea events alongside substantial weight loss.

Again, the significance of these results extends beyond weight loss itself.

Modern obesity medications are increasingly being evaluated according to whether treating obesity improves its downstream complications.

What Are the Side Effects?

The safety profile remains critically important because a medication capable of producing large physiological effects can also produce meaningful adverse effects.

Across retatrutide studies, the most frequently reported adverse events have been gastrointestinal, including:

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • decreased appetite

In the Phase 2 obesity trial, gastrointestinal adverse events were generally mild to moderate, occurred more frequently at higher doses and could be partially reduced by starting at a lower dose and gradually escalating treatment.

Researchers also observed dose-dependent increases in heart rate. These increases peaked during the trial and subsequently declined, but cardiovascular safety remains an important component of continued evaluation.

More recent Phase 3 data have also identified dysesthesia, an abnormal skin sensation that can include heightened sensitivity, tingling or unusual sensations. In recently reported TRIUMPH-2 safety data, dysesthesia occurred more frequently with retatrutide than placebo and was generally mild to moderate.

As with any investigational drug, uncommon adverse events and longer-term safety signals may become clearer only after substantially larger populations have been exposed for longer periods.

That is precisely why Phase 3 trials and regulatory review are necessary.

What About Muscle Loss?

Large amounts of weight loss introduce another important issue: weight loss and fat loss are not synonymous.

Whenever someone loses a substantial amount of body weight, some portion may come from lean tissue as well as adipose tissue.

This is relevant not only to retatrutide but to GLP-1-based obesity treatment generally.

Preserving skeletal muscle is particularly important during major weight loss because muscle contributes to physical function, metabolic health, strength and healthy aging.

If retatrutide eventually becomes an approved obesity treatment, maximizing outcomes will likely involve more than simply taking a weekly injection. Appropriate nutrition, adequate protein intake and progressive resistance exercise may remain important components of comprehensive obesity management.

The goal should not simply be maximum weight loss.

The more meaningful objective is improved body composition, metabolic health, physical function and long-term health.

Retatrutide Is Not Currently an FDA-Approved Medication

This point deserves particular emphasis.

As of October 2026, retatrutide has not been approved by the FDA or any other regulatory agency. Lilly says it plans to submit a regulatory application to the FDA in the first quarter of 2027.

That means consumers cannot currently obtain an FDA-approved retatrutide prescription.

This has not prevented an underground market from developing.

Products labeled “retatrutide” are being advertised online, through social media, by peptide sellers and in some medical-spa or telehealth settings.

Consumers should understand that these are not FDA-approved retatrutide products.

In fact, the FDA now explicitly states that retatrutide cannot legally be used in compounding under current federal law because it is not a component of an FDA-approved drug and does not meet the applicable requirements for bulk substances used in human drug compounding.

FDA warning letters have already targeted businesses marketing purported compounded retatrutide.

The problem extends beyond regulatory technicalities.

An unapproved product purchased online may contain an incorrect concentration, contaminants, impurities, a different peptide or no meaningful amount of the advertised ingredient.

Lilly warns that retatrutide is currently legitimately available only to participants in its clinical trials and specifically cautions consumers against products claiming to contain the drug.

Could Retatrutide Represent the Next Generation of Obesity Treatment?

Potentially.

The progression from GLP-1 agonism to dual GIP/GLP-1 agonism and now triple GIP/GLP-1/glucagon agonism represents a broader evolution in metabolic pharmacology.

Instead of targeting a single pathway, researchers are attempting to reproduce or modify multiple hormonal signals involved in energy homeostasis.

Retatrutide's Phase 2 and Phase 3 results suggest that this approach can produce unusually large reductions in body weight.

But efficacy is only one dimension of a successful therapy.

Regulators will also evaluate safety, tolerability, treatment discontinuation, cardiovascular outcomes, manufacturing quality and whether benefits outweigh risks across the intended patient population.

Another unanswered question concerns long-term treatment.

Obesity is increasingly understood as a chronic biological disease rather than a temporary failure of willpower. If retatrutide behaves similarly to existing incretin therapies, maintaining its benefits may require continued treatment for many patients.

Researchers will therefore need to understand what happens over years—not merely 40, 68 or 80 weeks.

The Bottom Line

Retatrutide is one of the most scientifically important investigational obesity medications currently in development.

Its defining feature is its triple mechanism of action, activating GLP-1, GIP and glucagon receptors with a single once-weekly molecule.

Clinical research has demonstrated substantial reductions in body weight, including average losses approaching 30% in certain Phase 3 populations, alongside improvements in glycemic control and several obesity-related complications.

Those results could potentially move pharmacologic obesity treatment closer to weight reductions historically associated with some forms of metabolic surgery.

But the scientific enthusiasm needs to be accompanied by an equally clear warning.

Retatrutide remains investigational. It is not FDA-approved. There is currently no legitimate FDA-approved “generic” or compounded retatrutide available to consumers.

The next major milestone will be regulatory review following Lilly's planned submission.

Until then, retatrutide should be viewed for what it actually is: a highly promising experimental metabolic therapy with compelling clinical data—but still an experimental therapy whose complete long-term benefit-risk profile is being established.

Educational disclaimer: This article is for educational purposes only and is not medical advice. Retatrutide is an investigational medication and is not currently FDA-approved. Medication decisions should be made with an appropriately licensed healthcare professional.

References

Peer-reviewed research, FDA guidance and manufacturer trial updates. Company announcements are not equivalent to independent peer-reviewed publications.

  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. View source
  2. FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — includes the restrictions on retatrutide compounding. View source
  3. Eli Lilly: Retatrutide development, clinical research and consumer safety information. View source
  4. Eli Lilly: TRIUMPH-1 Phase 3 topline results, May 2026 (manufacturer announcement). View source
  5. Eli Lilly: TRIUMPH-4 weight-loss and knee osteoarthritis results (manufacturer announcement). View source
  6. Eli Lilly: TRIUMPH-2 weight-loss and A1C results, September 2026. View source
  7. Eli Lilly: TRANSCEND-T2D-1 Phase 3 glucose-control and weight-loss results, March 2026. View source
  8. Retatrutide and liver fat in metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. View source

Related learning